Hampshire Hospitals NHS Foundation Trust and Sensyne Health have signed an agreement for the ethical application of clinical artificial intelligence (AI) research on anonymised patient data.
The five-year, non-exclusive strategic research agreement (SRA) will help to improve patient care and accelerate research into new medicines.
The dataset of Hampshire Hospitals covers 500,000 unique patient records, with 200,000 hospital admissions a year from a patient population of about 570,000 people.
This includes oncology data that will enable Sensyne to build on its existing research into rare cancers.
Under the new agreement, the combined total of anonymised data of the hospital available for analysis by Sensyne will now reach 6.1 million patients.
Sensyne Health CEO Lord (Paul) Drayson said: “Importantly, our agreement with Hampshire Hospitals and their oncology expertise now allows us to build on our capabilities in researching rarer forms of cancer.
“Following the recent achievement of our original patient data goal we’ll continue to use our resources efficiently, to add data consistent with our strategy of providing an unparalleled research resource for the healthcare and pharmaceutical sectors.”
Research will be undertaken to the highest standards of information governance in line with NHS principles, the UK Government Code of Practice and data protection legislation.
Hampshire Hospitals will anonymise all data supplied to Sensyne beforehand. The provision of the data will operate under an agreed data processing protocol.
The hospital will also receive 1,428,571 ordinary shares in Sensyne representing 1.11% of the existing issued share capital of the latter.
Additionally, it will receive an investment of up to £250,000 per year from Sensyne over the five-year term of the contract for specific investments in information technology.